Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
Medpage Today on MSN1d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart FailureCHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback